HYPER-STABILIZED LIPOSOMES INCREASING DIRECTED TARGETING OF MITOTIC CELLS Russian patent published in 2022 - IPC A61K9/127 A61K31/00 A61K47/02 

FIELD: medicine.

SUBSTANCE: group of inventions relates to the field of medicine, namely to hyper-stable liposome for the treatment of cancer, containing an internal medium separated from an external medium by membrane, where the internal medium contains an antimitotic drug, two cations enclosed in the internal medium, where the antimitotic drug is a polo-like kinase inhibitor, where membrane contains 1,2-distearoyl-sn-glycerin-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSFE-PEG2000), hydrogenated egg L-α-phosphatidylcholine (HEPC), and cholesterol (Chol), where the molar ratio of HEPC:Hol:DSFE-PEG2000 is 50:45:5, where two anions are citrate and phosphate, citrate and acetate or acetate and phosphate in a molar ratio of 1:3 or 1:4, and where the enclosed antimitotic drug has a slow release rate from hyper-stable liposome, which is quantitatively less than 0.6% in 12 hours or less than 5% in 8 days, where hyper-stable liposomes are suspended in 600 mM sucrose, it also relates to a liposomal composition for the treatment of cancer, containing hyper-stable liposome in an aqueous medium and to a pharmaceutical composition for the treatment of cancer containing hyper-stable liposome and a pharmaceutically acceptable excipient, it also relates to hyper-stable liposome for use as a drug for the treatment of cancer in a subject.

EFFECT: group of inventions provides for the creation of liposomes that maximize the temporary effect of an agent inhibiting mitosis in order to increase the proportion of dividing cancer cells that can be affected by the agent inhibiting mitosis.

15 cl, 2 tbl, 14 dwg, 5 ex